Floatz logo

Polyiclc

Platinum-Resistant Fallopian Tube Carcinoma

National Cancer Institute (NCI)Phase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Platinum-Resistant Fallopian Tube Carcinoma cohort.

Asset / SponsorPhaseRating
Guadecitabine
National Cancer Institute (NCI)
Phase 2BB
Atezolizumab
Ronald Buckanovich
Phase 2/3BB
Durvalumab
National Cancer Institute (NCI)
Phase 2BB
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
National Cancer Institute (NCI)
Phase 2B
Irinotecan Sucrosofate
Northwestern University
Phase 2B

View all 27 →

Same molecule, other indications

Polyiclc is also rated in:

Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
B
Indicative ·
63 / 100
View asset →
melanomaDormant
B
Indicative ·
63 / 100
View asset →
ocular melanomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →